文献速递免疫规划慢病防控与筛查

重症肌无力患者流感疫苗接种的前瞻性双盲随机安慰剂对照研究

A prospective, double-blind, randomized, placebo-controlled study on the efficacy and safety of influenza vaccination in myasthenia gravis.
PubMed 文献 · Vaccine · 2019-01-16

该前瞻性双盲随机安慰剂对照研究纳入47例乙酰胆碱受体抗体阳性重症肌无力(AChR MG)患者,比较流感疫苗与安慰剂接种后4周的抗体应答与安全性。结果显示AChR MG患者对疫苗株的血清保护率与47例健康对照相近,免疫抑制治疗未显著影响接种后GMT,疾病特异性AChR抗体滴度及临床评分未见恶化。

要点

  • AChR MG患者接种流感疫苗后血清保护率与健康对照相近。
  • 免疫抑制药物未显著影响接种后抗体几何平均滴度。
  • 接种后4周AChR抗体滴度与MG临床评分未见恶化。

核心结论

  • AChR MG患者对流感疫苗的抗体应答与健康受试者无差异,即使正在使用免疫抑制药物。
  • 流感疫苗接种不引起AChR MG的免疫学或临床加重。

研究设计与样本

  • 前瞻性、双盲、随机、安慰剂对照研究,纳入47例AChR MG患者。
  • 47例健康对照接种相同流感疫苗以比较抗体滴度。
  • 接种前及接种后4周采集血样并记录临床结局评分。

主要发现

  • H3N2株接种后血清保护滴度(HI≥1:40)在MG组为89.4%、健康对照组为93.6%。
  • H1N1株血清保护率MG组95.7%、健康对照组97.9%。
  • B株血清保护率MG组46.8%、健康对照组51%。
  • 三株均达血清保护者MG组40.4%(19/47)、健康对照组51%(24/47)。
  • 接种后4周疾病特异性AChR抗体滴度未变,临床结局评分未显示MG症状加重。

关键数值与推荐

  • 血清保护定义为血凝抑制试验(HI)滴度≥1:40。
  • 免疫抑制药物对接种后几何平均滴度(GMT)无显著影响。

临床怎么用

  • 可为AChR MG患者(包括使用免疫抑制药物者)接种流感疫苗,无需担心诱发疾病加重。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the efficacy and safety of an influenza vaccination in patients with myasthenia gravis with acetylcholine receptor antibodies (AChR MG). METHODS: An influenza vaccination or placebo was administered to 47 AChR MG patients. Before and 4 weeks after administration blood samples and clinical outcome scores were obtained. Antibodies to the vaccine strains A/California/7/2009 (H1N1)pdm09, A/Hong Kong/4801/14 (H3N2) and B/Brisbane/060/08 were measured using the hemagglutination-inhibition (HI) assay and disease-specific AChR antibody titers were measured with a radio-immunoprecipitation assay. Forty-seven healthy controls (HC) were vaccinated with the same influenza vaccine to compare antibody titers. RESULTS: A post-vaccination, seroprotective titer (HI ≥ 1:40) was achieved in 89.4% of MG patients vs. 93.6% in healthy controls for the H3N2 strain, 95.7% vs 97.9% for the H1N1 strain and 46.8 vs 51% for the B-strain. A seroprotective titer for all three strains of the seasonal influenza vaccine was reached in 40.4% (19/47) of the MG group and in 51% (24/47) of the HC group. Immunosuppressive medication did not significantly influence post geomean titers (GMT). The titers of disease-specific AChR antibodies were unchanged 4 weeks after vaccination. The clinical outcome scores showed no exacerbation of MG symptoms. CONCLUSION: The antibody response to an influenza vaccination in patients with AChR MG was not different from that in healthy subjects, even in AChR MG patients using immunosuppressive medication. Influenza vaccination does not induce an immunological or clinical exacerbation of AChR MG. CLINICAL TRIAL REGISTRY: The influenza trial is listed on clinicaltrialsregister.eu under 2016-003138-26.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Strijbos E, Tannemaat MR, Alleman I, et al. A prospective, double-blind, randomized, placebo-controlled study on the efficacy and safety of influenza vaccination in myasthenia gravis. Vaccine. 2019. PMID: 30660402. doi:10.1016/j.vaccine.2019.01.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。